Get the Stockscreener App
0.1692
0.41%
-0.0009
Gossamer Bio Inc stock is traded at $0.1692, with a volume of 4.01M.
It is down -0.41% in the last 24 hours and down -17.41% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
See More
Previous Close:
$0.1701
Open:
$0.172
24h Volume:
4.01M
Relative Volume:
0.16
Market Cap:
$82.76M
Revenue:
$55.54M
Net Income/Loss:
$-180.40M
P/E Ratio:
-0.2148
EPS:
-0.7877
Net Cash Flow:
$-170.32M
1W Performance:
+9.50%
1M Performance:
-17.41%
6M Performance:
-60.13%
1Y Performance:
-92.94%
1-Day Range:
$0.164
$0.1733
1-Week Range:
$0.1457
$0.2137
52-Week Range:
$0.1138
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.1693 | 76.99M | 55.54M | -180.40M | -170.32M | -0.7877 |
VRTX
Vertex Pharmaceuticals Inc
|
541.86 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.05 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,031.30 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.44 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.34 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-24-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-24-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-24-26 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Gossamer Bio (NASDAQ:GOSS) Funding Move Signals Biotech Shift - Kalkine Media
Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA Approval - Pulse 2.0
Latham Advises Gossamer Bio on Structured Private Placement - Latham & Watkins LLP
Latham Advises Gossamer Bio on Up to US$250 Million Structured Private Placement, Including US$150 Million of Committed Capital - Legal Desire
Gossamer Bio Slips as $250M Financing Hinges on FDA ApprovalGossamer Bio (NASDAQ:GOSS) - Benzinga
Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Chall - GuruFocus
Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval - Yahoo Finance
Gossamer Bio Secures Up to $250M to Advance Seralutinib Toward FDA Approval - citybiz
$Gossamer Bio (GOSS.US)$ yessir 🦁 mode still early - Moomoo
Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Challenging Valuation Landscape - GuruFocus
Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell - marketscreener.com
Gossamer Bio secures up to $250m in milestone-based financing - Investing.com
$Gossamer Bio (GOSS.US)$ @traderslink_this_guy@TradersLink__ we never lacking 🤷♂️ 😉 - Moomoo
Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants - TradingView
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval - Yahoo Finance
Gossamer Bio, Inc. announced that it expects to receive $250 million in funding - marketscreener.com
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Revenue per share of Gossamer Bio, Inc. – HAM:4GB - TradingView
Gossamer Bio achieves exceptional financial eff... - Pluang
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib - Yahoo Finance
GOSS Maintained by Piper Sandler -- Price Target Lowered to $4.0 - GuruFocus
Gossamer Bio Inc (GOSS) News, Articles, Events & Latest Updates - Stocktwits
GOSS|Gossamer Bio Inc|Price:0.154|Chg%:-0.016 - TradingKey
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
$Gossamer Bio (GOSS.US)$ This is the bottom - Moomoo
Gossamer Bio: Q2 Earnings Snapshot - AOL.com
Gossamer Bio Q2 Results: EPS beats estimate, sales up 78% vs view - scanx.trade
Is Gossamer Bio Inc (GOSS) Undervalued After Q2 Earnings Beat? G - GuruFocus
Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer Bio, Inc. 2026: Revenue $9.24M, Net income $16.9M, EPS ($0.08) — 10-Q Summary - TradingView
Gossamer Bio reports Q2 2026 net income of $16.9M; cash $57.0M, NDA submission for seralutinib on track - TradingView
Gossamer Bio (GOSS) cuts debt but flags going concern and liquidity strain - Stock Titan
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio Company Profile & Introduction - Moomoo
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm - Morningstar
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio - The National Law Review
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
gossamer bio inc. Earnings dates - RTTNews
Gossamer Bio Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Gossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update - Yahoo Finance
BlackRock (GOSS) discloses 4.89M-share, 1% beneficial stake in Gossamer Bio - Stock Titan
$Gossamer Bio (GOSS.US)$ call me crazy but atlease you calling... - Moomoo
GOSS Upgraded by Leerink Partners -- Rating Changed to Outperform - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Leerink Partners Upgrades Gossamer Bio to Outperform From Market Perform, $1 Price Target - marketscreener.com
Leerink upgrades Gossamer Bio stock rating on FDA feedback By Investing.com - Investing.com UK
Gossamer Bio (NASDAQ:GOSS) Shares Surge as FDA Progress Highlights Path Forward; Cash Covenant Looms as Next Hurdle - TechStock²
Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment - Moomoo
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):